News
MRK
144.30
+0.34%
0.49
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot
Seeking Alpha · 7h ago
Moderna, Illumina lead healthcare gains in September as medtech drags
Seeking Alpha · 10h ago
Dividend Champion, Contender, And Challenger Highlights: Week October 4
Seeking Alpha · 1d ago
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
NASDAQ · 1d ago
8 Of 11 Sectors Rise Friday As Growth Leads
Benzinga · 1d ago
Shattuck Labs price target raised to $14 from $11 at Wedbush
TipRanks · 1d ago
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
Seeking Alpha · 1d ago
Merck (MRK) Advances Tulisokibart After Positive Phase 2b Hidradenitis Suppurativa Data
Simply Wall St · 1d ago
3 ETFs to Buy with At Least 13% Upside Potential, According to the AI Analyst
TipRanks · 2d ago
Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating
TipRanks · 2d ago
Spyre Therapeutics price target raised to $130 from $121 at Jones
TipRanks · 2d ago
Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained
TipRanks · 2d ago
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
NASDAQ · 2d ago
Press Release: Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
Dow Jones · 2d ago
Why Citi Is Sounding the Alarm on Moderna Stock
Barchart · 2d ago
RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)
TipRanks · 3d ago
Merck (MRK) Stock Still Looks Reasonable On Its 110% Run
Simply Wall St · 3d ago
FDA launches recruitment drive to add members to advisory panels
Seeking Alpha · 3d ago
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline
Barron‘s · 3d ago
Merck, 3M share losses contribute to Dow's 286-point drop
MarketWatch · 3d ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.